DDInter1309 DDInter1676
A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Nizatidine {u} (Compound) resembles {v} (Compound) Ranitidine
Nizatidine {u} (Compound) binds {v} (Gene) HRH2
Nizatidine {u} (Compound) upregulates {v} (Gene) RAB27A
Nizatidine {u} (Compound) is included by {v} (Pharmacologic Class) Histamine H2 Receptor Antagonists
Nizatidine {u} (Compound) downregulates {v} (Gene) SLC35B1
Nizatidine {u} (Compound) causes {v} (Side Effect) Sinusitis
Nizatidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Flurbiprofen
Nizatidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ketorolac
Nizatidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bosutinib
Nizatidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gefitinib
Nizatidine (Compound) resembles Ranitidine (Compound)
Nizatidine (Compound) binds HRH2 (Gene)
Nizatidine (Compound) upregulates RAB27A (Gene)
Nizatidine (Compound) is included by Histamine H2 Receptor Antagonists (Pharmacologic Class)
Nizatidine (Compound) downregulates SLC35B1 (Gene)
Nizatidine (Compound) causes Sinusitis (Side Effect)
Nizatidine may cause a minor interaction that can limit clinical effects when taken with Flurbiprofen
Nizatidine may cause a minor interaction that can limit clinical effects when taken with Ketorolac
Nizatidine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Nizatidine may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib